Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
daratumumab
Biotech
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
Sanofi will learn whether the FDA will approve anti-CD38 antibody isatuximab in multiple myeloma by the end of April 2020.
Nick Paul Taylor
Jul 10, 2019 8:15am
J&J bags $150M option on Genmab's Darzalex successor
Jun 11, 2019 8:13am
Genmab files for $500M IPO to fund multi-front cancer R&D push
May 29, 2019 7:42am
Sanofi’s Darzalex rival hits primary endpoint in phase 3
Feb 5, 2019 9:50am
MorphoSys sells China rights to Darzalex rival in $120M deal
Nov 30, 2017 9:35am
